At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
osimertinibdrug
Likely dose
osimertinib 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm Phase II Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
In Brief
A Phase 2 clinical trial evaluating osimertinib for Non Small Cell Lung Cancer. Completed, enrolled 17 participants across 3 sites.
Detailed Summary
This is a research study to find out if a drug called, osimertinib, is safe and effective in treating advanced Non-Small Cell Lung Cancer (NSCLC) by targeting the treatment of epidermal growth factor receptor (EGFR) mutation exon 18 G719X, exon 20 S7681, or exon 21 L861Q. Patients on the study will not have had previous tyrosine kinase inhibitor (TKI) treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartJun 2018
Primary CompletionOct 2022
TodayJul 2026
First PostedFeb 15, 2018
Enrollment StartJun 30, 2018
Primary CompletionOct 12, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 8.4 years ago
Interventions
osimertinibdrug
80 mg oral administration daily